Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$25.16 USD

25.16
40,162,120

+0.51 (2.07%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $25.14 -0.02 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 245)

Industry: Large Cap Pharmaceuticals

Zacks News

Mark Vickery headshot

CPI +0.6%: Higher, but Not Scary; JNJ Vax on Hold?

Headline CPI last month reached +0.6%, 10 basis points ahead of consensus, and the highest single-month tally since June of 2009.

Zacks Equity Research

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $36.97, moving +1.01% from the previous trading session.

Zacks Equity Research

Stock Market News for Apr 12, 2021

Benchmarks hit record levels on Friday, closing in the green for consecutive weeks as investors shrugged off inflation fears and focused on quarterly earnings season amid reopening optimism

Zacks Equity Research

J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots

The European drug regulator's safety committee is conducting a review to asses a link between J&J's (JNJ) COVID-19 vaccine and rare blood clots.

Zacks Equity Research

Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

Zacks Equity Research

ImmunityBio (IBRX) Reports Positive COVID-19 Vaccine Data

ImmunityBio (IBRX) reports positive initial data on its COVID-19 vaccine candidate in healthy phase I study participants.

Zacks Equity Research

Higher-Than-Expected PPI in March

Higher-Than-Expected PPI in March.

Zacks Equity Research

Merck (MRK) Keytruda Meets Endpoint in Kidney Cancer Study

Merck (MRK) is developing a Keytruda monotherapy regimen for adjuvant treatment of renal cell carcinoma patients.

Mark Vickery headshot

PPI Doubles Month Over Month to 1.0%

We haven't seen a higher headline PPI figure since the fallout of the pandemic era, now more than a year ago.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes

FDA delays decision on Pfizer (PFE), AbbVie (ABBV) and Lilly's (LLY) filings for JAK inhibitor candidates. AstraZeneca's (AZN) COVID-19 vaccine troubles continue.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Zacks Equity Research

AstraZeneca (AZN) COVID-19 Jab May Have Link to Rare Blood Clots

European regulators find a possible link between AstraZeneca's (AZN) COVID-19 vaccine and rare blood clot events.

Zacks Equity Research

Pfizer (PFE) Dermatitis JAK Inhibitor NDA Review Gets Delayed

The FDA extends the review period of Pfizer's (PFE) candidate abrocitinib in atopic dermatitis by three months.

Zacks Equity Research

AstraZeneca (AZN) COVID-19 Vaccine Dosing Halted in Kids Study

Oxford University pauses dosing in AstraZeneca's (AZN) COVID-19 vaccine study in children until U.K. regulator completes review of fresh rare blood clot events.

Zacks Equity Research

Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

Zacks Equity Research

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Pfizer (PFE) closed at $36.28, marking a -0.06% move from the previous day.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Johnson & Johnson, Delta Air Lines, Southwest Airlines and United Airlines

The Zacks Analyst Blog Highlights: Pfizer, Johnson & Johnson, Delta Air Lines, Southwest Airlines and United Airlines

Zacks Equity Research

The Zacks Analyst Blog Highlights: JPMorgan, Verizon, Chevron, Pfizer and QUALCOMM

The Zacks Analyst Blog Highlights: JPMorgan, Verizon, Chevron, Pfizer and QUALCOMM

Sheraz Mian headshot

Top Research Reports for JPMorgan, Verizon & Chevron

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Verizon Communications (VZ), and Chevron (CVX).

Maharathi Basu headshot

CDC's New Guidance Makes the Skyline Sunnier for U.S. Airlines

CDC's latest travel manual provides a further impetus to the U.S. airline stocks like Delta (DAL), Southwest Airlines (LUV) and American Airlines (AA), which are scaling an outstanding graph on the bourses this year.

Zacks Equity Research

SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study

SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.

Zacks Equity Research

AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

Zacks Equity Research

J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant

The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.

Zacks Equity Research

Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo

Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.

Zacks Equity Research

Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day

Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day